The acquisition of Congenica by the Montpellier company Seqone illustrates a strategic evolution of the clinical genomic in Europe. By uniting French software expertise and a British platform from Wellcoma Sanger Institute, this operation gives birth to the largest world player exclusively focused on genomic analysis software.
Since the 100,000 Genomes Project launched in the United Kingdom and the French Medicine Plan Genomic 2025, several European countries are investing in national infrastructure. However, the fragmentation of initiatives remains a brake. Each program produces massive data but struggles to integrate into a common ecosystem. By combining Seqone’s interpretation tools and Congenica’s clinical experience, the operation provides an industrial response to this dispersion.
“The rapid pace of personalized medicine requires continuous investment in software innovation and advanced specialization,” said Martin Dubuc, CEO of Seqone. “By integrating the CONGENICA team, we strengthen our growth trajectory and our ability to provide advanced software as well as expert interpretation services. Beyond the discourse, the challenge is to constitute a pan-European platform capable of supporting laboratories and health systems in the analysis and clinical use of genomic data.
The question of interpretation remains the point of tension because if the cost of sequencing drops quickly, transforming this information into reliable diagnoses remains complex. It is on this ground that global competition is played out and Europe has scientific and clinical assets, like the NHS or French-university hospital centers, but it remains behind the construction of global industrial actors.
With more than 160 customer laboratories in around thirty countries and an objective of 200,000 genomic analyzes in 2025, the French company opens the possibility of an integrated European trajectory.
The financial conditions of the agreement were not made public. The operation comes a few months after the buyout of Life & Soft and a raising of 20 million euros in 2025, confirming Seqone’s desire to build a complete platform, capable of establishing itself as a standard for European genomic medicine.
